Odyssey Thera Granted U.S. Patent for Novel GPCR Assa... ( Claims extend and strengthen Odyssey ...)

Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy

Date:2/12/2009

Claims extend and strengthen Odyssey Thera's coverage to include GPCR directed screening and drug profiling.

SAN RAMON, Calif., Feb. 12 /PRNewswire/ -- Odyssey Thera, Inc. announced today that it has been granted a United States patent entitled "Fragment Complementation Assays for G-Protein-Coupled Receptors and their Signaling Pathways." The patent broadly covers methods for screening compounds and for identifying drug leads based on their ability to activate, inhibit or otherwise modulate G-protein-coupled receptors and the diverse signaling pathways linked to these receptors.

"This patent further extends and strengthens our deep patent estate in drug discovery and development technologies," said John K. Westwick, Ph.D., Odyssey Thera CEO and co-author on the patent. "GPCRs are among the most valued targets for drug discovery, and our proprietary technologies enable GPCR-directed drug discovery in a native biological context. The fluorescence-based assays described in this patent are the only available strategy for capturing GPCR activities, including responses of hetero-dimeric GPCR complexes and diverse downstream effector proteins, in living human cells. These powerful new tools are essential in our search for more effective therapies for cancer and other un-met medical needs."

This is the thirteenth patent issued to Odyssey Thera, and solidifies its leadership position in cellular assay and drug discovery technologies. The inventions covered by this patent (U.S. Patent No. 7,488,583) were made by Odyssey Thera scientists.

About Odyssey Thera, Inc.

Odyssey Thera, Inc. is a drug discovery company building therapeutic pipelines for oncology and other chronic diseases. Odyssey Thera's pathway-based approach centers on its proprietary protein-fragment complementation assay (PCA) technology, as well as the considerable body of trade secrets it has developed in sc
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Odyssey Thera Granted U.S. Patent for Animal Imaging
2. Stereotaxis Highlights a Transatlantic Arrhythmia Procedure Collaboration With the Odyssey(TM) Network
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. LI-COR Introduces the Odyssey(R) Two-Color NIR Fluorescent Protein Molecular Weight Marker
5. Technical Note: E-PAGE(TM) 48- and 96-Well Gels on the Odyssey(R) Infrared Imaging System
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
8. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
9. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
10. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
11. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway

Post Your Comments:

Odyssey Thera Granted U.S. Patent for Novel GPCR Assa...( Claims extend and strengthen Odyssey ...)